Raymond James & Associates
PDLI

Raymond James & Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

Raymond James & Associates’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,008
Closed -$36K – 3678
2017
Q4 		$36K Buy
13,008
+1,341
+11% +$4.12K ﹤0.01% 3307
2017
Q3 		$40K Buy
+11,667
New +$32.4K ﹤0.01% 3258
2014
Q1 		– Sell
-53,001
Closed -$447K – 2194
2013
Q4 		$447K Sell
53,001
-7,359
-12% -$62K ﹤0.01% 1715
2013
Q3 		$481K Buy
60,360
+22,295
+59% +$179K ﹤0.01% 1620
2013
Q2 		$294K Buy
+38,065
New +$297K ﹤0.01% 1716

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Raymond James & Associates's PDLI Position: Q1 2018 in Review

Raymond James & Associates sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 13,008 shares — an estimated $36K sold.

Raymond James & Associates first reported a position in PDLI in Q2 2013 and held it in 5 quarters. The position peaked at $481K in Q3 2013. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

  • Raymond James & Associates reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
  • Raymond James & Associates sold 13,008 PDL BioPharma, Inc. shares in Q1 2018, an estimated $36K.
  • Raymond James & Associates first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 5 quarters.
  • Raymond James & Associates's PDL BioPharma, Inc. position peaked at $481K in Q3 2013.
  • 176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.